Source:http://linkedlifedata.com/resource/pubmed/id/18462372
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2009-1-26
|
pubmed:abstractText |
Dopamine agonists have been reported to increase the risk of cardiac valve regurgitation in patients with Parkinson's disease. However, it is unknown whether these drugs might be harmful for patients with hyperprolactinaemia (HyperPRL). The aim of the study was to evaluate whether HyperPRL patients treated with dopamine agonists had a higher prevalence of cardiac valves regurgitation than that of general population.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1742-1241
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1864-9
|
pubmed:meshHeading |
pubmed-meshheading:18462372-Adult,
pubmed-meshheading:18462372-Aortic Valve Insufficiency,
pubmed-meshheading:18462372-Case-Control Studies,
pubmed-meshheading:18462372-Dopamine Agonists,
pubmed-meshheading:18462372-Ergolines,
pubmed-meshheading:18462372-Female,
pubmed-meshheading:18462372-Humans,
pubmed-meshheading:18462372-Hyperprolactinemia,
pubmed-meshheading:18462372-Male,
pubmed-meshheading:18462372-Mitral Valve Insufficiency,
pubmed-meshheading:18462372-Risk Factors,
pubmed-meshheading:18462372-Tricuspid Valve Insufficiency
|
pubmed:year |
2008
|
pubmed:articleTitle |
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
|
pubmed:affiliation |
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. f.bogazzi@endoc.med.unipi.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|